Study of efavirenz over 96 weeks shows durability, efficacious regimen. Results from 48-96 weeks essentially same.
Recent results from the Daily Antiretroviral Therapy (DART 1) trial show promising results for antiretroviral naïve patients. The 96-week study results from 65 patients who were treated with the combination of once-daily efavirenz (600 mg), lamivudine (300 mg), and didanosine (400 mg) showed that the rates of patients achieving HIV-1 RNA viral loads of less than 400 copies were essentially the same as the previous 48-week results.
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D010078:Oxazines / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D019562:Viral Load
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz